FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133048> ?p ?o ?g. }

• W4308133048 endingPage "A809" @default.
• W4308133048 startingPage "A809" @default.
• W4308133048 abstract "Abstract Background Teprotumumab, an FDA-approved insulin-like growth factor-1 receptor inhibitor for TED, improves proptosis, diplopia, inflammation, and quality of life. In the pooled phase 2 and 3 trial analysis, 8/84 (10%) teprotumumab-treated patients reported hyperglycemia adverse events (AEs) versus 1/86 (1.2%) in placebo. Here, we discuss perturbations in serum glucose data reported in patients from two pivotal clinical trials with teprotumumab. Methods Glycemia data from two randomized, double-masked, placebo-controlled multicenter trials were analyzed throughout 8 teprotumumab vs. placebo infusions. Blood glucose was measured at Weeks 1, 4, 15, and 21 in phase 2 study patients. In phase 3, all patients with pre-existing diabetes had blood glucose measured at each study visit. Patients without pre-existing diabetes had fasting blood glucose measurements at Weeks 1 and 4. The remainder of blood glucoses in non-diabetics were non-fasting. HbA1c levels were measured at baseline, 12 and 24 weeks, in all patients. Results The mean patient age was 51.4 years, with 73% female. At baseline, diabetic patients were controlled with oral and/or insulin therapies at primary investigator discretion. Mean baseline non-fasting blood glucose in teprotumumab patients was 98.3 mg/dl versus 100.5 mg/dl in placebo. Mean non-fasting blood glucose increased from baseline in teprotumumab-treated patients by 6.9 mg/dl but decreased by 6.5 mg/dl in those receiving placebo at 24 weeks. Nine hyperglycemia AEs were reported in 8 teprotumumab-treated patients; 6 resolved during the treatment period, 2 resolved after the last dose, and 1 continued after study completion. Five of 8 patients who had hyperglycemia had pre-existing diabetes in this pooled analysis. All reported hyperglycemic AEs were Grade 1 (&gt;160mg/dl) or 2 (161 mg/dl to 250 mg/dl). In the teprotumumab group follow-up, two patients had hyperglycemia-related AEs. One resolved without medication. Neither led to study drug discontinuation. HbA1c increased by 0.22% (mean, N=72) with teprotumumab compared to 0.04% (N=71) with placebo. There were no cases of diabetic ketoacidosis or hyperosmolar hyperglycemic state. Conclusion Approximately 10% of teprotumumab treated patients compared to 1% receiving placebo had hyperglycemic events. Most hyperglycemic cases were easily controlled with medication. In addition, no treatment discontinuation or complications were associated with these elevated blood glucose levels. This analysis demonstrates no evidence for severe diabetogenesis with teprotumumab treatment, although blood glucose monitoring is recommended for all patients. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m." @default.
• W4308133048 created "2022-11-08" @default.
• W4308133048 creator A5021326256 @default.
• W4308133048 creator A5036099998 @default.
• W4308133048 creator A5062231735 @default.
• W4308133048 creator A5066377208 @default.
• W4308133048 creator A5077112559 @default.
• W4308133048 creator A5083506910 @default.
• W4308133048 creator A5090194343 @default.
• W4308133048 date "2022-11-01" @default.
• W4308133048 modified "2023-09-24" @default.
• W4308133048 title "PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data" @default.
• W4308133048 doi "https://doi.org/10.1210/jendso/bvac150.1674" @default.
• W4308133048 hasPublicationYear "2022" @default.
• W4308133048 type Work @default.
• W4308133048 citedByCount "2" @default.
• W4308133048 countsByYear W43081330482022 @default.
• W4308133048 countsByYear W43081330482023 @default.
• W4308133048 crossrefType "journal-article" @default.
• W4308133048 hasAuthorship W4308133048A5021326256 @default.
• W4308133048 hasAuthorship W4308133048A5036099998 @default.
• W4308133048 hasAuthorship W4308133048A5062231735 @default.
• W4308133048 hasAuthorship W4308133048A5066377208 @default.
• W4308133048 hasAuthorship W4308133048A5077112559 @default.
• W4308133048 hasAuthorship W4308133048A5083506910 @default.
• W4308133048 hasAuthorship W4308133048A5090194343 @default.
• W4308133048 hasBestOaLocation W43081330481 @default.
• W4308133048 hasConcept C126322002 @default.
• W4308133048 hasConcept C134018914 @default.
• W4308133048 hasConcept C142724271 @default.
• W4308133048 hasConcept C197934379 @default.
• W4308133048 hasConcept C204787440 @default.
• W4308133048 hasConcept C27081682 @default.
• W4308133048 hasConcept C2779306644 @default.
• W4308133048 hasConcept C2780668416 @default.
• W4308133048 hasConcept C535046627 @default.
• W4308133048 hasConcept C555293320 @default.
• W4308133048 hasConcept C71924100 @default.
• W4308133048 hasConcept C90924648 @default.
• W4308133048 hasConceptScore W4308133048C126322002 @default.
• W4308133048 hasConceptScore W4308133048C134018914 @default.
• W4308133048 hasConceptScore W4308133048C142724271 @default.
• W4308133048 hasConceptScore W4308133048C197934379 @default.
• W4308133048 hasConceptScore W4308133048C204787440 @default.
• W4308133048 hasConceptScore W4308133048C27081682 @default.
• W4308133048 hasConceptScore W4308133048C2779306644 @default.
• W4308133048 hasConceptScore W4308133048C2780668416 @default.
• W4308133048 hasConceptScore W4308133048C535046627 @default.
• W4308133048 hasConceptScore W4308133048C555293320 @default.
• W4308133048 hasConceptScore W4308133048C71924100 @default.
• W4308133048 hasConceptScore W4308133048C90924648 @default.
• W4308133048 hasIssue "Supplement_1" @default.
• W4308133048 hasLocation W43081330481 @default.
• W4308133048 hasLocation W43081330482 @default.
• W4308133048 hasOpenAccess W4308133048 @default.
• W4308133048 hasPrimaryLocation W43081330481 @default.
• W4308133048 hasRelatedWork W2045993936 @default.
• W4308133048 hasRelatedWork W2055794815 @default.
• W4308133048 hasRelatedWork W2057262151 @default.
• W4308133048 hasRelatedWork W2057434408 @default.
• W4308133048 hasRelatedWork W2058969843 @default.
• W4308133048 hasRelatedWork W2076754594 @default.
• W4308133048 hasRelatedWork W2081101301 @default.
• W4308133048 hasRelatedWork W2083753940 @default.
• W4308133048 hasRelatedWork W2097857221 @default.
• W4308133048 hasRelatedWork W2121663374 @default.
• W4308133048 hasVolume "6" @default.
• W4308133048 isParatext "false" @default.
• W4308133048 isRetracted "false" @default.
• W4308133048 workType "article" @default.